Confluence is a Contract Research Organization providing Clients with 125+ Years of Drug R&D know-how and a proven track record having delivered 29 Phase I and 13 Phase II drug programs that resulted in 4 marketed drugs.
Confluence is located in the CORTEX Bioscience District adjacent to the Washington University School of Medicine in St. Louis, Missouri. Our highly trained scientists operate a state-of-the-art laboratory to support biochemistry and enzymology, cell and molecular biology, custom assay development, translational research, as well as computational and medicinal chemistry to ensure your project’s success.
The Confluence Team provides services from one time consultation to independently driving a drug discovery program.
Working closely with clients we assess project scope and needs while providing problem solving, strategy development and testing funnel design.
At project implementation we collaborate as integral team members providing technical expertise and service along with frequent data updates and the flexibility to adjust to changing project needs.
CDT offers cellular assay development and screening.
Target, Mechanism and Disease Biomarkers identified, validated and executed across a wide range of targets, species and biological matrices.
We are leaders in mechanistic enzymology and focus on custom assay development. Screen your compound library in our sensitive, reliable assays that are easily scaled to meet your throughput needs. We can look at compound:target interaction, enzyme inhibitor mechanisms and direct binding kinetics.
We have the expertise to evaluate the mechanisms of action studies by characterization of binding mechanisms (competitive, noncompetitive, uncompetitive, irreversible, slow tight binding and aggregate) and binding kinetics (time-dependence and steady-state). We also provide progress curve analysis.
Our experienced team provides mechanism of inhibition studies, looking at competitive vs noncompetitive, uncompetitive, irreversible vs slow tight binding and aggregate (non drugable).
Using multiplex technologies such as MSD and Luminex, CDT can measure secreted proteins, intracellular proteins and look at signaling pathways.
CDT provides whole blood and PBMC cytokine release assays.
CDT offers SPR assays, using the Biacore 2000, to measure the binding affinity (Kd).
SPR Real Time Binding for
- Quantitation of target affinity
- Determination of binding kinetics
- Evaluation of specificity
- Competition epitope mapping
Small Molecule Drug:
- Determination of affinity to target: enzyme, receptor, other macromolecular target
- Binding kinetics
- Target specificity
CDT offers project management and provide strategy with critical milestones and timelines. We can design and implement a testing funnel with clear compound advancement criteria.
CDT offers cytotoxic T cell killing assays (using mouse splenocytes). Using differential labeling of control and specific target cells, allows quantification of killing.
CDT offers the B cell activation assay in human Ramos B cell line.
T cell subsets are generated in vitro from naive lymphocytes or whole splenocytes when treated with appropriate antibodies and "skewing" cytokines.
Inflammation is the hallmark of allergy, infectious diseases, and wound healing. It is a leading cause of mortality worldwide and is indicated in eight major disease areas including autoimmune diseases, cancer, cardiovascular diseases, diabetic complications, infectious diseases, metabolic disorder complications, neurological diseases, and pulmonary diseases.
CDT offers custom multiplex inflammation assays that can detect and quantify biomarkers of inflammation from the TNF superfamily proteins, IFN family proteins, Treg cytokines, and MMPs.
Cell signaling pathway analysis by ELISA, western blot, FACS, Luminx and MSD analysis.
High-throughput 96-well format, custom designed or kit-based ELISAs. CDT can analyze serum, plasma, cell lysates, cell culture supernatants. We can measure cytokines, transcription factors, protein phosphorylation, histone acetylation etc.
PBMC isolation and neutrophil isolation from human/rat whole blood
CDT provides both enzyme and cellular assay development and screening. We work closely with our clients to understand their needs and set critical milestones and timelines.
CDT offers transient transfection of mammalian cells in both adherent or suspension cell cultures.
CDT provides PK/PD studies to support the early stages of the drug discovery process. Routes can be IV, oral gavage, tail vein etc.
CDT offers FACS analysis for rapidly analyzing a large number of cells individually using light-scattering, fluorescence, and absorbance measurements.
CDT offers a broad range of custom cloning services at a reasonable cost. We offer essentially all recombinant DNA services, including gene synthesis, PCR cloning, plasmid vector design and construction.
Industry leading enzymologists at CDT provide Drug:target assays, looking at binding kinetics (Kon and Koff).
CDT provides services for RNA, miRNA, and DNA samples, including RNA/DNA extraction, RNA quality control and quantification and cDNA synthesis for quantitative-PCR; and QRT-PCR.
Methylation of proteins, nucleic acids and oligosaccharides is an important post- translational regulatory event. CDT offers end-point or kinetic read options, which are ideal for determining mechanism of action, kinetics, and screening candidate compounds.
CDT offers Schrodinger enabled structure based drug design.
CDT offers cell signaling pathway analysis by multiplexing, ELISAs and western blot.
CDT offers in vitro ADME/Tox assays. We also offer genetic toxicology, safety pharmacology and general toxicology.
CDT offers protein purification for any small to mid-scale, non-GMP protein purification projects.
CDT offers a broad range of services related to drug target validation such as pathway-based approach to target ID or validation.We also offer many services related to the identification and validation of relevant biomarkers and drug targets.
Confluence Discovery Technologies has not received any reviews.
Confluence Discovery Technologies has not received any endorsements.